Sign in
Click here - to use the wp menu builder
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Monday, December 23, 2024
Sign in / Join
Facebook
Instagram
Twitter
Vimeo
Youtube
Pharma Deals
Update
Oncology
Search
Home
Authors
Posts by pharmaquotient.com
pharmaquotient.com
60 POSTS
0 COMMENTS
http://pharmaquotient.com
Merger & Acquisition
Collegium Pharmaceutical to Acquire Ironshore Therapeutics, Expanding into Neurology
pharmaquotient.com
-
29 July 2024
0
Clinical update
Hisamitsu Pharmaceuticals Announces data of HP-6050, an one of a kind transdermal sedative in Japan
pharmaquotient.com
-
1 July 2024
0
Licensing Agreement
Kissei Pharmaceuticals enters into Licensing Agreement for GnRH Antagonist Linzagolix with JW Pharmaceutical Corporation in Korea
pharmaquotient.com
-
10 June 2024
0
Merger & Acquisition
AbbVie Acquires Landos Biopharma for NX-13
pharmaquotient.com
-
23 May 2024
0
Oncology
Merck Announced Discontinuation of Phase 3 KeyVibe-010 Trial Investigating Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
pharmaquotient.com
-
13 May 2024
0
Pharma Deals
AbbVie and Gilgamesh Pharmaceuticals Collaborates to Develop Therapies for Psychiatric Disorders
pharmaquotient.com
-
13 May 2024
0
Clinical update
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial...
pharmaquotient.com
-
9 May 2024
0
Business Strategy
Merck Expands Access to High-Quality Maternal Care for More Than 30 Million Women Worldwide Through Merck for Mothers
pharmaquotient.com
-
8 May 2024
0
Clinical update
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or...
pharmaquotient.com
-
1 May 2024
0
Business Strategy
AbbVie Invested €150 M to Develop R&D Facility in Germany.
pharmaquotient.com
-
30 April 2024
0
1
2
3
...
6
Page 2 of 6
TOP AUTHORS
constance80t
0 POSTS
0 COMMENTS
Neha Tripathi
1 POSTS
0 COMMENTS
http://pharmaQuotient.com
pharma analyst
0 POSTS
0 COMMENTS
pharmaquotient.com
60 POSTS
0 COMMENTS
http://pharmaquotient.com
Most Read
Neuralink’s Blindsight: A Breakthrough in Vision Restoration
20 September 2024
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
17 September 2024
Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.
9 September 2024
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7 September 2024